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Alzheimer’s disease is the most common type of dementia; causing problems with memory, think-
ing and behaviour. The seemingly protective effect of hormone replacement therapy against
Alzheimer’s disease sparked an interest in the role of the sex hormone system. Sex steroid
production is dependent on gonadotropins released in the pituitary. The gonadotropin level is
controlled by gonadotropin releasing hormone and its receptor (GnRH-R) is dispersed through-
out the body, but is interestingly expressed on neurons in the same brain regions affected by
Alzheimer’s disease. Positron emission tomography (PET) is a non-invasive imaging technique
which utilises radioactively labeled molecules. A radioactively labelled GnRH-R antagonist
allows for the observation and quantification of GnRH-R density which may reflect early patho-
logical changes in Alzheimer’s disease.
This thesis includes the synthesis, fluorination and biological in vitro evaluation by human
serum stability of four piperazine tert-butyl benzimidazole GnRH-R antagonist analogues via
direct halide exchange from chloroalkyl precursors.
Three compounds were successfully fluorinated in the last reaction step. The reactions all
had reaction times less than 30 minutes, suitable for radioactive labelling where a short reaction
time is essential. In the last part of this thesis, the three fluorinated compounds were tested for
stability in human serum and incubated for 22 hours. All of the fluorinated compounds showed
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• DMSO: Dimethyl Sulfoxide
• EtOAc: Ethyl Acetate
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1 Introduction
There were an estimated 46,8 million people living with dementia in 2015 and it is estimated that
this number will almost double every 20 years. The increased longevity leads to a population
where people are getting older than before and the prevalence of dementia increases. Dementia
usually affects elderly, even though there is a growing awareness of early onset dementia. The
costs of dementia is immense, estimated to be a trillion US$. To put it into perspective: if
dementia was a country, it would be the 18th largest country in the world. A large portion of
the people living with dementia does not have the formal diagnosis, not getting treatment and
creating a treatment gap.[1]
The World Alzheimer report from 2011 underlined the importance of early diagnosis in
closing the treatment gap. An early diagnosis can improve disease progression through drug
and non-drug interventions and prepare the patient leading to delayed institutionalisation and
greater quality of life. The patient can make important life decisions before becoming too
cognitively impaired and the surrounding family can get information and support on how to
handle this disease.[2]
1.0.1 Alzheimer’s Disease
Alzheimer’s Disease (AD) is the most common type of dementia, being the cause of approxi-
mately 60% of the dementia patients. AD is categorised as early or late onset based on if the
onset was before or after the age of 60.[3]
AD is a chronic progressive neurodegenerative disease. The symptoms can be divided into
three primary groups: (1) Cognitive dysfunction which manifests as memory loss, language
difficulties and lack of planning abilities. (2) Psychiatric symptoms such as depression, halluci-
nations and agitation. (3) Daily living difficulties like eating, shopping and dressing.[4]
AD is categorised into three stages by NIA (National Institute on Aging). The preclinical
stage is when the brain changes, but clinical symptoms are not prominent. This can then
progress to mild cognitive impairment (MCI) where symptoms start to emerge. The last stage
is the Alzheimer’s dementia diagnosis with all or some of the symptoms stated above.[4] [5]
The disease is characterised by neurofibrillary tangles, β-amyloid plaque and cell loss. The
neurofibrillary tangles are caused by the hyperphosphorylation of tau proteins, and the low
solubility of β-amyloid leads to aggregation which is toxic to the neurons and ultimately leading
to cell loss.[3]
The research into β-amyloid plaques is vast, but pharmacotherapy targeting these has shown
little effect.[6] This indicates that these physiological changes are secondary to the AD and is
caused by the underlying mechanisms and not themselves a cause of AD.[7]
1.0.2 Diagnosis
The physician makes the diagnosis based on the patient’s ability to function normally and the
presence of cognitive and behavioural symptoms and through thorough investigation of the
patient’s history and neuropsychological testing.[5][8] We divide the dementia diseases based on
the physiological cause: (1) The degenerative brain diseases which include AD, Huntingtons and
Parkinson, (2) Vascular dementia and (3) Secondary dementia caused by other non-degenerative
diseases in the brain.[8] Vascular dementia usually has a more sudden onset than AD and is an
important factor in the differential diagnosis.
Brain imaging has traditionally been performed using magnetic resonance imaging (MRI)
and computed tomography (CT) to observe atrophy (reduction in size) in certain areas of the
brain. Positron Emission Tomography (PET) (discussed later in this chapter) has gained more
and more interest as resolution and radiotracer availability has increased. PET uses different
radioactive tracers to observe binding in the brain. Trials has been done using fluordeoxyglucose
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(FDG), tau protein binders and β-amyloid binders to stage AD.[9][10] Most PET-tracers can
be useful in the differential diagnosis of dementia, but there is still missing good radiotracers
for the early diagnosis.
1.0.3 Risk factors
Risk factors include age, genetic predispositions for example diseases affecting the chromosomes
such as Down’s disease, ApoE (Apolipoprotein E) genotypes and head injuries.[4] Lifestyle
diseases like Diabetes Mellitus, hypertension[11][12], obesity, physical inactivity and smoking
also gives an increased risk of AD. Barnes et al.[13] estimates that a reduction in these lifestyle
diseases by 25% will reduce the prevalence of AD cases with 3 million worldwide.
1.0.4 Pharmacotherapy
There is no cure or effective treatment of AD today, but there are drugs that help with
some of the symptoms.[8] Pharmacotherapy mainly focuses on cholinesterase inhibitors such
as donepezil, rivastigmine and galantamine. Their mechanism of action is the blocking of
cholinesterase enzymes that breaks down acetylcholine, thereby increasing the concentration of
naurotransmitter in the synaptic gaps. Their efficacy is well documented to be beneficial for
people with AD, although the effects are small and the clinical importance discussed.[14][15][16]
There are also another class of drugs that block NMDA-receptors (N-methyl-D-aspartate) in
glutamatergic neurons. Drugs include memantine and the class has showed good results in sev-
eral studies.[17][18] Patients with AD also has an increased drug burden using in average more
drugs than other controls without cognitive diseases.[19]
1.1 Gonadotropins
Gonadotropins are a part of the endocrine system. The endocrine system consists of a range
of hormones controlling bodily functions and activities together with the nervous system. The
bodily functions include metabolism and electrolyte balance, regulating temperature, stress
response, blood cell production and growth and reproduction. The gonadotropins are tropic
hormones, meaning that their primary function is the regulation of hormone secretion by other
glands. Gonadotropins act on the gonads, which is the reproductive glands that stimulates the
production of gametes (sex cells) and sex hormones.
Gonadotropins are a group of polypeptide hormones including Follicle-stimulating hormone
(FSH) and Leuteinizing Hormone (LH). The gonadotropins are essential to the production of
sex hormones and disturbances in the release of gonadotropins leads to unnormal growth, lack
of sexual development and infertility.
The anterior pituitary gland is responsible for the production of gonadotropins and gets its
signals from the hypothalamus. The hypothalamus secretes Gonadotropin Releasing Hormone
(GnRH), a decapeptide (pGlu−His−Trp−Ser−Tyr−Gly−Leu−Arg−Pro−Gly−) which
binds to its receptors (GnRH-Rs) in the anterior pituitary gland leading to the production and
secretion of LH and FSH.[20] The GnRH-Receptors are G-protein coupled receptors mainly
located in the anterior pituitary gland, but can also be found on neoplastic cells. GnRH is
used clinically in two ways: to mimic the normal GnRH cycle in patients with infertility or to
block the receptor in the treatment of sex-hormone dependent cancers such as prostate, ovary
or mammary.[21] The main focus in this thesis is the gonadotropins’ connection to Alzheimer’s




LH, GnRH and activins have receptors throughout the body, including neurons and these recep-
tors are regulated by hormonal feedback. The hormones and their receptors regulate different
processes in the the brain and the dysregulation during meno- and andropause can cause changes
in the brain and may be a driver for degenerative diseases such as AD.[23]
The hypothalamus-pituitary-gonadal-axis (HPG-axis) consists of the hypothalamus, pitu-
itary gland and the gonads. Testosterone and oestrogen are released in the gonads from stim-
uli by gonadotropins produced in the pituitary gland. Testosterone and oestrogen will then
have a negative feedback on the pituitary gland. During meno- and andropause oestrogen and
testostoreone, respectively, decreases. The testosterone and oestrogen levels decrease and the
negative feedback on the pituitary gland leads to increased gonadotropin hormones. The levels
of LH and FSH are significantly elevated in women with AD compared with normal controls.[24]
The sex hormones are steroids made from cholesterol. Cholesterol is stored in lipoproteins
which transports lipids around the body. Apolipoproteins are proteins on the outside of lipopro-
teins and bind to the Low-density lipoprotein receptor. ApoE has three phenotypes, E2, E3
and E4. Having the E4 is a known risk factor for developing AD.[25]
1.1.2 Gonadotropins and Alzheimer
Each gonadotropin plays a role in the aging and changing brain. Estrogens and androgens
shows a trophic and neuroprotective ability and decreasing concentrations has been connected
to disease progression through epidemiological studies. Early studies on the meno-/andropauses
influence on AD showed HRT to reduce the risk of AD through reduction of tau phosphorylation
and β-amyloid plaques [25][26][27][28][29], but these believes are now being questioned.[30][31]
Studies now show that Hormone replacement therapy (HRT) has a critical period in which it
exerts its effect [29] and this critical period corresponds with the peak time of GnRH levels.
The hormone levels are directly related to the gonadotropin levels due to the negative feedback
loop. It was then hypothesized that it may not be the levels of oestrogen and testosterone, but
the levels of gonadotropins that played a crucial role.
Gonadotropin levels has shown to be elevated in AD patients compared to age-matched
controls and the increased risk of AD in women can be explained by the earlier and more sud-
den rise in gonadotropin levels. The gonadal hormone receptors are located throughout the
brain, but is concentrated in the limbic system and are known for regulating brain develop-
ment and brain structure. The same neurons that is a part of the AD pathology.[27] Several
studies has shown that LH levels modulate Amyloid-β Protein Precursor (AβPP) and the gen-
eration of β-amyloid. This is supported by mouse studies eliminating the effect of sex hormone
alterations.[32][33][34][35]
During meno- and andropause the GnRH-levels are close to that of an infant, and as this is
a phase of growth and GnRH activins and sex steroids are promoters of cell proliferation it’s
likely that this promotes the signals for development in the brain.[23] Studies have shown that
the AD brain undergoes cell signalling indicative of cell cycle activity and the reintroduction
of neuronal cells in this cycle. Adult neuronal cells normally stop at the G0-phase and remain
in this state through adult life. The AD brain surprisingly shows that neuronal cells shows
activated pathways ultimately leading to cell death and atrophy.[36][23] This hypothesis is
further explained by the biochemical changes like Aβ-plaques, tangles and hyperphosphorylation
of tau and presenilin expression is evident in the infants developing brain. These changes are
present in the developing brain (where neuronal cells die during the shaping of the brain) and
support that Aβ-proteins are a part of cell death and tau-phosphorylation in the division of
cells, destabilizing the microtubule.
This mechanism can also be explained by the observed increase in AD risk for people with
Down’s syndrome.[25] [37] The Down’s syndrome patient has sex-hormone levels comparable
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to the normal population, but their gonadotropin levels are significantly higher. Especially the
gonadotropin FSH is increased in these patients and contrary to the normal population, this
occurs more frequently in male patients.
Studies has shown that gonadotropins enhanced the number of LDL-receptors (Low Density
Lipoprotein) and their transport into neurons. Lipoproteins are globular complexes made of
proteins and lipids (fat) in the body and are responsible for the transport of fat through the
body. On the surface of these lipoproteins there are ligands known as Apolipoprotein E and its
receptor is β-amyloid. Individuals carrying a specific allele of the gene coding for this protein,
ApoE4 are known to have an increased risk of AD. The elevated circulating gonadotropin levels
could increase plaques formed from ApoE and its ligand β-amyloid if we assume that these
mechanisms are also present in neural cells.[25][38] This mechanism can also help to explain
the protective effect of HRT as increased testosterone and oestrogen levels would decrease the
gonadotropin levels and thereby reduce plaques.
Targeting gonadotropin release can affect the incidence and progression of AD, as showed
by Casadesus et. al when they treated late stage AD mice with leuprolide acetate showing im-
proved cognition and β-amyloyd depositions.[32] Leuprolide acetate is a GnRH analogue acting
as an agonist on the GnRHR initially inducing stimulation of gonadotropins, but since a steady
administration does not mimic the natural endogenic cycle the receptors soon become desensi-
tized and LH and FSH levels decrease. GnRH antagonists does not have this initial increase in
gonadotropins. As well as having the potential in therapy of AD, the GnRH antagonists has
the potential as PET tracers. This non-invasive tool can help us understand the expression of
GnRHR in AD and possibly prove to be a valuable diagnostic tool.
1.2 Positron Emission Tomography
Figure 1: A PET/CT-scan can be combined to give both structural and functional images [39].
Positron Emission Tomography (PET) is a nuclear imaging technique using small amounts
of a radionuclide to give functional images of uptake in the body. The most common radionu-
clide is [18F]-FDG (2-Fluoro-Deoxy-D-glucose), a glucose analogue which accumulate in energy
demanding cells such as cancerous, brain and heart.
The 18F is made in a cyclotron which accelerates and shoots protons at water enriched with
18O. When a proton ”crashes” into the nucleus of the 18O it kicks out a neutron and you are left
with 18F.[40] The reaction can be written like this: 18O (p, n) 18F. 18F– is a good nucleophile,
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but it makes strong hydrogen bonds with water creating a solvation effect making it almost
chemically inert. The 18F– is therefore extracted from the water using Kryptofix 222 ®, a
cryptand that complexes with K+ which creates a salt with the fluorine. The salt will be more
hydrophobic, allowing for the use of organic solvents. The rest of the water is usually removed
using acetonitrile (ACN) which makes an azeotropic mixture with water and makes it possible
to evaporate them together.
Figure 2: This shows the principle of PET on an atomic level. The readionuclide emit a β+-
particle which annihilates with an electron resulting in two γ-rays which is then detected.
As illustrated in Figure 2, radionuclides used in PET emit β+-particles, also known as
positrons. Positrons are similar to electrons, having the same mass but with a positive charge.
This makes the positron the antiparticle of an electron. The positrons are short-lived and only
travel a couple of millimetres in tissue until it meets an electron and annihilates into two γ-rays
of 511 keV almost 180° from each other. This angle is to maintain the momentum each of
the particles had when they were annihilating. 511 keV is the resting potential of an electron,
and the positron has to come close to this to be able to annihilate and is the reason for its
travel. It does not need to reach exactly 511 keV, the consequence being that the angle of which
the two γ-photons is not exactly 180°. The different radionuclides used in PET-scanning (11C,
13N, 15O, 18F and 68Ga) emit β+-particles with different energy levels. 18F, the most common
radionuclide has a decay energy of 634 keV, close to that of an electron’s resting potential. The
practical difference between the energy levels is the distance from where the radionuclide decays
to where the β+-particles annihilates with an electron. A simulation of positron travel between
68Ga and 18F shows that the 68Ga positron travels about three times further in lung tissue than
18F resulting in poorer resolution.[41]
PET gives good functional images as opposed to CT which gives structural information. To
interpret PET images alone can be difficult as it is difficult to localise the uptake in the body
since there is little structural information. The combined image obtained from a PET/CT gives
both radiotracer activity and its distribution.
The advantage of PET-scans is that it allows us to get structural and functional images of
the body, including the brain. This would be beneficial in understanding the development of
AD in patients as the disease progresses and the importance of GnRH-R expression.
Theranostics is an interesting field which is comprised of two words: therapy and diagnostics.
Within nuclear medicine the main focus of theranostics is cancer, where a PET-radiotracers can
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Figure 3: A SN2-reaction mechanism, most commonly done during nucleophilic substitution of
incorporating fluorine in PET tracers. This shows the nuclophilic fluoride attacking the carbon
and through a transition state kicking out chloride as the leaving group.
be used for diagnosis and stage-determination of the cancer and then radiolabelled with a nuclide
emitting more tissue damaging radiation. When changing the diagnostic radionuclide i.e. 18F
with a β−-emitter such as 177Lu, the radiation can be specific and the total radiation dose to the
patient minimised compared to conventional radiation therapy. One of the earlier theranostic
applications were the ”magic bullet” for thyroid cancer: 131I which emits both β− and γ-rays.
Since iodine is mainly absorbed in the thyroid gland to produce thyroid hormones, 131I can be
administered and will effectively irradiate the thyroid gland with β−. Since approximately 10%
of the 131I decay is γ-rays, the patient can also be examined using a single photon emission
computed tomography (SPECT), another nuclear medical modality.
1.3 Radiochemistry
1.3.1 PET radiochemistry
The synthesis of radioactive PET-tracers needs to be quick to increase radiochemical yields
due to the short half-life of most PET radionuclides.[42] The most common PET radionuclide
18F has a half-life of 109,7 minutes.[43] Since 18F usually is extracted using a class of crown
ethers called cryptands (Kryptofix), the most common way of incorporating the radionuclide is
nucleophilic substitution via SN2 shown in Figure 3. Direct nucleophilic substitution calls for
a good nucleophile and a good leaving group and most common in radiolabelling are tosylates
and mesylates.
1.3.2 The piperazine tert-butyl benzimidazole class
The synthesis of small molecule non-peptide GnRH-R antagonists has gained increasing scientific
interest. There are 10 different classes of non-peptide GnRH receptor antagonists including the
piperazine-benzimidazole derivatives presented in this thesis.[44]
The piperazine tert-butyl benzimidazole class has shown nanomolar binding affinities to the
human GnRH-R receptor and good oral bioavailability [45] making this a class of interest for
future optimisation.
Previous studies on similar compounds prepared to be SPECT-tracers, using radioactive
iodine showed certain instability issues in serum [46] In serum, the issue is thought to be the
hydroxylation, cleaving the C-I-bond.
1.3.3 Fluorination
As a further optimisation of these compounds we wanted to incorporate fluorine and prepare
them as potential PET-radiotracers The C-F-bond is a short bond (∼1.47 Å) and one of the
strongest bonds in organic chemistry[47] and should improve serum stability over the previously
synthesised iodides. The fluorination method is a direct primary alkyl halide substitution with
tetrabutyl ammonium fluoride (TBAF) as the fluoride carrier shown in Scheme 1.
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Scheme 1: The scheme shows the fluorination method used in this thesis and is adapted from
[48].
18F is, as described earlier made in a cyclotron from 18O-enriched water and traditionally
the preparation of radiolabelled pharmaceuticals were made with water as solvent. Even though
18F– is a strong nucleophile, the solvation effect of water reduces its reactivity substantially and
requires harsh reaction conditions.
Despite several methods of incorporating fluorine in organic molecules [49] relatively few
methods are used for radiolabelling because the introduction of 18F requires the method to
be selective, efficient and convenient.[50] To facilitate the [18F]-radiolabelling and improve the
reaction conditions it is now common to use a ”naked” fluoride ion attached to a cation such as
tetrabutylammonium or a crown ether complex.[51][50]
The ammonium salt creates a salt with fluorine making the fluorine less affected by the solva-
tion effect and fascilitating the nucleophilic fluorination. Because the fluorine ion is less covered
in solvents it is often referred to as ”naked”. TBAF is thought to mimic the Kryptofix222, a
cryptand wich binds a K+ creating a salt with F– .
As described earlier, the 18F– is bound to a carrier and the reaction usually performed in an
aprotic solvent such as ACN. Recent studies have shown that adding some amounts of a sterically
hindered protic solvents such as tert-butanol can maintain nucleophilicity while reducing by-
product formation and reduce reaction time substantially with.[50][48] The thought behind this
is that the sterically hindered protic solvent will help stabilise the fluorine and solubilise it. This
can help bring the fluorine to the molecule and initiate the SN2-reaction. Since the molecules
are prepared to become PET radiotracers it is an advantage to use late-stage radiolabelling
where the fluorine is incorporated in the molecule as late as possible.
Direct fluorination from chlorides is attempted according to [48]. This study uses a molecule
where the C–Cl carbon is more electron dense than in our short-chained molecules and thus
our molecules should have a faster reaction time than the reported 48 hours. The long reaction
time is not suitable for PET due to the short t1/2 of
18F and methods to reduce reaction time
is essential.
1.3.4 Microwave assisted synthesis
The method of using microwave to enhance reaction speed and selectivity is known within
organic synthesis and radiolabelling.[52] The matter undergoing microwave irradiation will heat
up as long as it has a dipole moment. The oscillation of the molecules corresponds to the
frequency, wavelength and energy of the irradiation and the fast changing in the electric field
leads to an even heating of the reaction mixture.[53] This heating and activation of molecules
help decrease reaction times substantially, which is sought after in a radiolabelling situation.
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1.4 Serum stability
Serum stability analysis is an important first step in the in vitro evaluation of potential new
drugs. Previously reported studies on an α-iodinated piperazine tert-butyl benzimidazole [46]
showed sufficient serum stability for rat brain SPECT analysis and biodistribution, but with
room for improvement. The previous studies were conducted with the aim of creating SPECT
radiotracers with radioactive iodine. SPECT as a nuclear medicine modality is still important,
but lack the possibility of quantification as obtainable in PET. To overcome these potential
problems, we want to synthesise fluorinated compounds which should be more stable than
iodinated molecules as well as develop a fluorination method indicating suitability for 18F-
radiolabelling.
A problem emerging from alkyl iodides, especially α-iodides such as presented in [46] is the
potential alkylation effect. In medicinal chemistry it is rarely a good thing to have α-halides
as these molecules has the potential of reacting with DNA and other nucleophilic aminogroups
and thiols in proteins. DNA consists of base-pairs, all of which contain nucleophilic nitrogen’s
that is able to attack the electron poor α-carbon leading to an irreversible alkylation of the
DNA-pair leading to cell damage and possible cancer. The same reaction is shown in Figure 3
where DNA in this instance would act as F– does in the figure.
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2 Aims
It is known that gonadotropins can play an important role in Alzheimer’s Disease. Small
molecule GnRH antagonists can help understand the mechanism behind gonadotropin involve-
ment in AD and may be used as a method for early diagnosis of the disease.
The first aim was to synthesise the intermediate Compound 5 as shown in Scheme 2 as
this forms the basis for the four chlorinated analogues which is the starting material for the
fluorination.
The second aim was to develop a fluorination method which was effective and provided
good yields as the last step in the synthesis. The fluorination in radioactive labelling preferably
happens in the last synthesis step to minimise time from radioactive labelling to finished product.
A good fluorination method would indicate suitability for 18F-fluorination and the possibility of
radioactive labelling and subsequent preclinical in vivo experiments. The fluorides are presented
in Figure 1.
The third aim was to determine the human serum stability of the fluorinated analogues and
compare them to previously reported iodide compounds. The serum stability has been an issue
with alkyl halides, making them less suitable as drugs. The serum stability would also give an
indication of the alkylating effect, giving rise to potential cytotoxic sideeffects.
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3 Results and discussion
The results and discussion chapter are divided into three sections: Firstly the synthesis of
intermediate and the chloroalkyl ketones which forms the basis of starting material for the
fluorination is presented. The second part presents the results of the fluorination method, its
effectiveness and the chloroalkyl moieties’ suitability as starting material. Finally the human
serum stability performed on the fluorinated products and compare them to a previously syn-
thesised iodoacetyl ketone with known human serum stability performance.
3.1 Synthesis of intermediate and analogues
The intermediate (Compound 5) presented in Scheme 2 is the starting material for the chloroalkyl
ketone analogues. The chloroalkyl ketones are produced by reacting the intermediate with
chloroacyl chlorides with different chain lengths to produce Compound 62, 63, 65 and 66. The
chlorinated is presented as starting material in Scheme 1.
The synthesis of intermediate (Compound 5) was done according to Pelletier et al.[54] with
the modifications done by Fjellaksel and colleagues [55].
Compound 5 was synthesised successfully with a total yield of 36% over five which is com-
parable to Fjellaksel [55] with synthetic route shown in 2.
Table 1: Key reaction data from the synthesis of intermediate Compound 5 as shown in Scheme











*increased NaN3 from 1 to 1,2 eq to increase yield from 83%
3.1.1 1-azido-3-fluoro-2-nitrobenzene Compound 1
2,6-difluoronitrobenzene was dissolved in dimethyl sulfoxide (DMSO) and 1,2 molar equivalents
(eq) NaN3 was added. The amount of NaN3 was increased from 1,0 to 1,2 equivalents to obtain
a yield of 98% compared to previously reported 83%[55] This could increase the disubstituted
by-product, but this would easily be removed in the next synthesis step as it can not react with
piperazine. The reaction mixture was extracted using ethyl acetate (EtOAc) and washed with
distilled water. If the water phase had a strong yellow colour, the water phase was washed with
EtOAc to minimise loss of product. The reaction is a nucleophilic aromatic substitution. The
product was confirmed using 1H-NMR, and the yield found to be 98%.
3.1.2 tert-butyl 4-(3-azido-2-nitrophenyl) piperazine-1-carboxylate Compound 2
Compound 1 was dissolved in DMSO and DIPEA and 1-boc-piperazine for a nucleophilic aro-
matic substitution. The N,N-Diisopropylethylamine (DIPEA) was added to increase pH and
ensure nucleophilicity of the 1-boc-piperazine. The reaction was stirred for 22 hours. The re-
action mixture was extracted using EtOAc and washed with distilled water. The organic phase
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Scheme 2: The scheme shows the synthetic route to reach the intermediate Compound 5
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was then dried on a rotavapor and the product dry mounted on celite and chromatographed
using flash chromatography. A 15:85 EtOAc : pentane mobile phase was first tried, but did
not give satisfactory separation and too many fractions making work-up more time consuming.
40:60 EtOAc : pentane gave a good separation and the best yields = 50%. The product was
confirmed using 1H-NMR.
3.1.3 tert-butyl 4-(2,3-diaminophenyl) piperazine-1-carboxylate Compound 3
Compound 2 was dissolved in methanol (MeOH) and transferred to a hydrogenation reaction
vessel. 10% Palladium on carbon (Pd/C) was carefully transferred to a test tube under constant
N2 stream and carefully added MeOH. Once the Pd/C was wetted with MeOH it was transferred
to the bomb which was mounted in the Parr apparatus. The reaction vessel was flushed with H2
three times to ensure a saturated atmosphere and maintained a pressure of 150 psi for 3 hours.
The reaction vessel was dismounted carefully and the reaction mixture filtered through celite
and the solvents removed on the rotavapor to provide a brown powder. The yield was found to
be 101% which indicates some solvent residues. The product was confirmed using 1H-NMR.
3.1.4 tert-butyl 4-(2-(4-(tert-butyl)phenyl) -1H-benzo[d]imidazol-4-yl) piperazine-
1-carboxylate Compound 4
Previous studies showed that the best yields could be obtained in the 1 mmol scale. Compound
3 was dissolved in ethanol (EtOH) and tert-butyl benzaldehyde was added to the solution and
heated to 80°C and the reaction refluxed for 24 hours. The aldehyde forms a cyclic structure
with the two amine groups obtaining the benzimidazole. The reaction was monitored using
Thin-layer chromatography (TLC) and stopped when the TLC started to show spots for the
unwanted disubstituted product (Figure 4) or there were no starting material left. The solvents
were removed using rotavapor and chromatographed using flash chromatography. The mobile
phase was a 40:60 EtOAc : pentane mixture. The fractions were collected and the solvents
removed on the rotavapor to obtain the desired product with 81% yield. The product was
confirmed using 1H-NMR.
Figure 4: The disubstituted by-product in the synthesis of Compound 4
3.1.5 2-(4-(tert-butyl)phenyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole Compound
5
Compound 4 was dissolved in 4M hydrochloric acid (HCl) in dioxane and stirred for 2 hours
to remove the Boc protection group. The solvents were removed using a water ejector vacuum
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pump with a trap between. When the solvents were removed, the product was extracted with
water and washed with EtOAc. The waterphase was lyophilized to obtain a white powder. The
product is the hydrochloride salt of Compound 5 and this was taken into account on the following
reactions. The yield were found to be 90%. The product was confirmed using 1H-NMR.
3.1.6 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-2-
chloroethan-1-one Compound 62
Compound 5 was dissolved in dry DMF under inert conditions and DIPEA was added to the
solution. The round bottom flask (RBF) was lowered into an ice bath. When the solution was
ice cold, chloroacetyl chloride was added to the solution dropwise. The solution was stirred
for 1 hour under N2. The reaction was quenched using distilled water and transferred to a
separatory funnel and washed with dichloromethane (DCM). Brine was used if the phases did
not separate. The organic phase was collected and evaporated on the rotavapor. The product
was chromatographed on Biotage C18 column and the fractions lyophilized to obtain a white
powder with a yield of 39% The product was confirmed using 1H-NMR.
3.1.7 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-3-
chloropropan-1-one Compound 63
The method for synthesising Compound 63 resembles the synthesis of Compound 62. Compound
five dissolved in dry dimethylformamide (DMF), added DIPEA and put in an ice bath. 3-
chloropropionyl chloride added to the solution dropwise. Main difference is the reaction time,
this reaction taking 3 hours. Work-up was done using a Biotage C18 column and the fractions




The method of synthesising Compound 65 resembles the synthesis of Compound 62. 5-chlorovaleroyl
chloride was added to ice cold reaction mixture of Compound 5, DIPEA and dry DMF. Purifi-
cation was done using a Biotage C18 column and the fractions lyophilized to obtain a white
powder yield = 28% The product was confirmed using 1H-NMR.
3.1.9 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-6-
chlorohexan-1-one Compound 66
The method of synthesising Compound 66 resembles the synthesis of Compound 62. 6-chlorohexanoyl
chloride was added to ice cold reaction mixture of Compound 5, DIPEA and dry DMF. Work-up
was done using a Biotage C18 column and the fractions lyophilized to obtain a white powder
yield = 28% The product was confirmed using 1H-NMR.
3.1.10 Improvements
Ultra Performance Liquid Chromatography (UPLC) analysis of the reaction showed the forma-
tion of 60% compound 72. The yield was found to be 30% and indicates that there is substantial
loss of product in the work-up. Sometimes the issue could be explained by overlapping peaks at
the Biotage as the difference in polarity between the chloride- and fluoride compounds is min-
imal. Better separation was seen on the preparative high performance liquid chromatography
(prep-HPLC) as can be expected from a bigger column with smaller silica particles. The use of
prep-HPLC was limited by technical instrument issues.
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3.2 Fluorination method
The fluorination method for radioactive labelling with 18F needs to be effective and selective to
maximise radiochemical yields.[42] The fluorination method was developed using non-radioactive
19F and conditions similar to that obtainable in a PET-center. Since 18F and 19F has the
same basic chemical properties there should not be a difference in reactivity between the two
isotopes, but some stoichiometric and condition differences must be expected and optimisation
and adjustments are anticipated in a potential radioactive labelling experiment.
The fluorination method uses TBAF shown in Figure 5 as the fluorine source because it was
available in the laboratory and mimics the cryptand. Few studies compare the two fluorination
methods head-to-head, but som future development must be expected if a crptand is used. Due
to the relatively long reaction time reported by Kim and colleagues [48] the method presented
in this thesis was a microwave-assisted reaction. The TBAF available in the laboratory was
a 1M solution in tetrahydrofuran (THF), a polar aprotic solvent. The reactions were done
at 160°C with 5 minute holds for a total of 30 minutes. The samples were analysed on high
resolution Mass spectrometry (HRMS) to follow the reaction and check for product formation.
The samples were later analysed on UPLC to determine reaction time showed in Figure 7.
Figure 5: Tetrabutyl ammonium fluoride
3.2.1 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-2-
fluoroethan-1-one Compound 72
The chloride analogue was dissolved in dry ACN in a microwave vial and 2 eq 1M TBAF (Figure
5) in THF was added to the solution. The reaction is a halide substitution. Since chlorine is not
the best leaving group and halide substitutions previously has been reported to have reaction
times up to 48 hours[48] the reaction was attempted in the microwave. The microwave was
set for 160°C for a total of 30 minutes with samples taken every 5 minutes. The samples were
analysed on HRMS during the reaction and later on UPLC to determine reaction time and
efficiency. The UPLC data concluded that the reaction was done after 5 minutes as there was




This reaction did not lead to the desired product. The chloride analogue was dissolved in dry
ACN in a microwave vial and 2 eq 1M TBAF in THF was added to the solution. The reaction
was done in the microwave at 160°C for a total of 30 minutes. The reaction was chromatographed
on Biotage C18 column. During work-up of this product, HRMS was utilised to detect which
fractions contained the desired product. The results did not show the mass of the desired
product, but instead found the mass corresponding to the elimination product shown in Figure
6.
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Figure 6: The elimination by-product formed in the attempted synthesis of Compound 73
3.2.3 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-5-
fluoropentan-1-one Compound 75
This reaction was done in the same way as the other fluorinations, but with substantial formation
of by-products compared to Compound 72. The product was worked up using Biotage and the
fractions containing product was confirmed using HRMS. The yield was found to be 15%.
3.2.4 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-6-
fluorohexan-1-one Compound 76
Due to adequate amounts of starting material it was decided to test the difference in selectivity
and reaction time when the reaction was dissolved in either tert-butanol or dry ACN. The
reaction mixtures were prepared with the same amount of starting material, solvent and TBAF.
The reaction was monitored using HRMS and even though MS is not quantifiable without
the use of internal standard calibration, the peak heights could give an indication of relative
abundance. The HRMS-results indicated that the reaction with tert-butanol were marginally
slower than the one performed in ACN, but the tert-butanol seemed to provide less of the
elimination product. They were both worked up using Biotage and the fractions containing
product was confirmed using HRMS. Yield from tert-butanol experiment: 31% Yield from ACN
experiment: 18%.
3.3 Reaction time experiment
Figure 7 shows the reaction time of direct fluorination with chlorine as a leaving group in dried
ACN. The graph shows the results from a single experiment, but similar results were observed
for every reaction. The peak height was determined by the UPLC-peak height and showed that
the reaction peaked at 60% product after 5 minutes and stayed consistently at that level. After
5 minutes, there was no more starting material left, indicating 40% other reaction products. In
addition to the product peak there were four other peaks: One larger peak found to be 18% of
the total area and the other three around ∼5%. The fractions were not worked up and analysed,
but it is known that TBAF is a weak base and it is speculated that the acidic α-protons leaves,
leading to an elimination of the chloride resulting in an olefin as the one shown in Figure 6.
It was estimated that the shorter chained molecules would have a faster reaction time than
the longer carbon chained. The reactions were monitored using HRMS, even though not quan-
tifiable the peak height can give an indication on relative abundance. The MS results confirmed
that reaction time was somewhat slower for the longer chained compounds, but all reactions
were completed within 30 minutes at 160°C in the microwave. As can be seen in Figure 7
the graph shows that the longer chained Compound 75 had 10% starting material left after 5
minutes, but never went down to 0%. The UPLC-spectra was difficult to analyse due to the
presence of other peaks with similar retention times which could contribute to the peak height
leading to an overestimation of starting material left.
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Figure 7: The reaction time of the two compounds, 72 and 75. Direct fluorination from chloride
monitored by UPLC at 0, 5, 10, 15, 20 and 30 minutes at 160°C in the microwave
The fluorinated compounds were purified by first extracting the reaction mixture with an
organic solvent and washed with distilled water. The organic phase were dried and the prod-
uct was further purified using C18 Biotage flashchromatography columns. The fractions were
collected based on HRMS results and lyophilized to obtain the pure product used in the serum
analysis.
The reaction time using microwave-assisted reaction are satisfactory with reaction times not
exceeding 30 minutes. The main issue found in this experiment is the by-product formation
and is considerably higher than Kim et al. [48] which reported 60% yield from a compound
comparable to that of Compound 75 which yielded 20% when using ACN.
The by-product formation can arise from a multitude of factors such as leaving group,
solvents used and fluorine source It would be interesting to compare the fluorination efficacy
with other leaving groups such as tosylates or mesylates which could increase yields as shown
by Pilcher and colleagues [56]. Pilcher also compared two different fluorine sources: TBAF and
TBAT (tetrabutylammonium (triphenyl- silyl)difluorosilicate). TBAF is considered having a
greater nucleophilicity than TBAT, but TBAT is less basic. This means that the reaction time
is expected to be longer, but the by-product formation should be less. In this experiment, where
the reaction times are low, a slightly longer reaction time with less by-product formation might
be beneficial.
Even though polar aprotic solvents generally are considered good solvents for nucleophilic
halide exchange reactions, there has been an increased interest of using sterically hindered protic
solvents. Kim et. al[48] compared the yields and reaction time in a nucleophilic fluorination
using a sterically hindered protic solvents such as tert-amyl- or tert-butyl alcohol and a polar
aprotic solvent such as ACN. In this comparison experiment in the synthesis of Compound 76,
the yields obtained were 31% using tert-butanol and 18% using ACN as solvent. Even though
the results presented in this thesis does not reach the same yields as Kim et. al. reported (95%
in tert-butanol and 59% in ACN), the trends are similar. Using HRMS during this reaction it
was apparent that the reaction time seemed longer in tert-butanol than ACN, but both reactions
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were completed at 30 minutes. This indicates that higher yields than presented in the other
fluorination could be obtained using tert-butanol. The other fluorination reactions were not
performed in tert-butanol because ACN is the solvent traditionally used in a PET-centre and
the method presented should resemble these conditions.
The fluorination method presented above showed adequate yield for three of the four at-
tempted fluorination. Compound 72, 75 and 76 were successfully synthesised and purified.
3.4 Human serum stability
The identification and optimisation of characteristics and properties of a compound are impor-
tant in drug development. A good lead candidate must possess good binding, potency, low
toxicity and stability. The stability analysis compared the three fluorinated compounds synthe-
sised in this thesis with a iodoacetyl ketone analogue previously synthesised by Fjellaksel et. al.
[57] (Compound 82) shown in Figure 8.
Fluorinated products are generally thought of as more stable than the other halides (Cl, Br, I



































Internal standard Compound 72 Compound 82
Compound 75 Compound 76
Figure 8: The compounds used in the serum stability study and the internal standard.
The stability testing was done by dissolving the compound in 5% ethanol, 5% polysorbate
80 and 90% water to make a 4µM solution. 50µl solution was added to 400µl serum and aliquots
of 50µl were taken at timepoints 0, 10, 30, 60, 120, 240 and 1320 (22h) minutes. The aliquots
were quenched with ice cold ACN and centrifuged at 13000 rpm for five minutes. 50µl of the
supernatant was transferred to HPLC-vial and 950µl internal standard (IS) solution was added.
The samples where then frozen until it were analysed on HPLC-MS. The serum experiments
were performed in triplicates.
The IS was added after the work-up and primarily served the purpose of reducing instrument
variations and not variations in the method. A new batch of IS was made before each stability
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test. The IS chosen was a compound previously synthesised in [55] and was used because it had
a mass similar to our compounds. The IS’s stability in water was tested to ensure that it would
not influence the measured stability. This was tested by freezing two HPLC-vials with a 85µM
solution and keeping two HPLC-vials with the same solution at room temperature for 24 hours.
Analysis showed that 95% of the IS was left after 24 hours.
The results presented in Figure 9 are ratios of the compound peak compared to the IS.
To ease the comparison, the results are presented as relative ratios where all the samples are
compared to t = 0 min. This ensures that all the lines start at the same point.
Figure 9: The human serum stability of compounds 72, 75, 76 and 82. The graph show that
the fluorinated compounds 72, 75 and 76 shows good stability in human serum compared to the
iodinated short-chained compound 82.
Figure 9 shows the stability of Compound 72, 75, 76 and 82 in human serum. The figure
shows that all the fluorinated compounds 72, 75 and 76 are more stable than the iodinated
compound 82. The fluorinated compounds all show that more than 90% of the product remains
after 22 hours. There are some fluctuation in the graphs, but common for the fluorinated
compounds is a increase towards the end. The IS stability experiment showed that 95% of the
IS was left after 24 hours. Since the graph is presented as a ratio between compound peak
height and IS peak height, this could overestimate the amount. To minimise the effect the IS
stability would have, a fresh batch was made before each experiment so that each compound
could be compared.
The figure confirms the assumptions that the C-F bond is more stable than C-I. It has
previously been known that α-halides next the electron withdrawing groups such as amides and
other carbonyls can exhibit alkylating mechanisms. These are therefore not considered good
drug candidates as alkylating agents can be cancerous through the alkylation and modification
of DNA. Since the main stability issue is thought to be the elimination of the halide, the serum
stability can give an indication of alkylation effect. Based on these stability data, the fluorides
should not possess this alkylation effect.
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The iodinated compound 82 showed greater stability in this study compared to previously
reported data [46], but the trends are similar. Previously reported stability for compound 82
showed that 50% remained after 1 hour and 23% after 2 hours [46].
In the development of the MS method there were some carry-over of the previous samples.
After changing the needle wash to a stronger solution containing more ACN this effect was
minimal and should not affect the results.
The IS had a retention time similar to a lot of signals from the serum and some of the varia-
tion in results can be explained by this. A suitable IS added at the same time as the compound
could eliminate method variations such as pipette volume variations and condensation on the
eppendorf test tubes and subsequently reducing the amount of variation.
The detector used was an orbitrap MS and ion suppression due to several other ions can
make the results vary. MS results can be quantifiable if it’s calibrated with a standard solution.
Before the samples were analysed, standards with known concentrations were made so that we
could quantitatively compare the concentration of compound in each sample. When performing
the analysis of the samples, substantial disturbances from the serum were observed in the same
retention time as the IS. The disturbances can the suppress the signal from the IS making it
lower than expected. Because the signal suppression would lead to a reduction in IS peak height,
the compound concentration would be overestimated in the serum samples if it was compared
to the standard without serum. Under the presumption that the serum LC-MS peaks did not
vary substantially between each sample, the IS peak could still be used to correct for instrument
variation. None of the compounds peaks had the same retention time as disturbances from the
serum and should not be affected by the ion suppression effect.
In the analysis of Compound 82, one of the three parallels was excluded as an outlier as
the concentration measured was only 15% of the other two parallels. This was due to too little
solution prepared making it difficult to measure out the correct amount before adding it to the
serum. The other two parallels were consistent in the concentration declined, but only having
two parallels explains the wider standard deviation.
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4 Conclusions
In this thesis, we presented the synthesis of three fluorinated compounds, adding to the existing
library of small-molecule piperazine tert-butyl benzimidazoles.
We synthesised the intermediate Compound 5 in 36% yield, which is comparable to previous
studies. The four chloroalkyl analogues were successfully synthesised with yields ranging from
28 to 65%.
One of the most important contributions of this thesis was to develop a fluorination method
for 19F fluorination with potential for 18F radiolabelling. The direct halide exchange method
proved useful and gave adequate yields in the fluoro-ethanone (Compound 72), -pentanone
(Compound 75) and -hexanone (Compound 76) using microwave. No desired product was
formed in the attempted fluorination of the chloro-propanone analogue (Compound 63). The
fluorination method had good reaction times, all reaction done within 30 minutes. The formation
of by-products should be further improved.
In the last part of this thesis we presented the human serum stability of the three fluorinated
compounds (Compound 72, 75 and 76). The study showed good serum stability after 22 hours
proving that these alkyl fluorides are suitable for further in vivo and in vitro experiments.
5 Future work
This thesis presented the 19F fluorination with low reaction times and usable yields. The
synthesis could be improved to increase yields and some methods has been discussed. Even
though 18F and 19F has mostly the same chemical properties, reaction conditions is expected to
be different in a PET-environment. A cryptand such as Kryptofix and TBAF are expected to
exert different fluorination selectivity and future experiments with radiolabelling should expect
some method development.
None of the analogues presented has been tested for binding affinities against the GnRH-R,
which is essential before future development. Should the compounds show satisfactory binding,
future in vitro and in vivo studies such as toxicological testing, biodistribution and preclinical
PET can be performed.
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All chemicals were bought from Sigma-Aldrich. Silica gel 60 TLC plates with fluroscence indi-
cator (F254) from Merck were used.
Instrumentation:
Microwave: Anton Parr Monowave 300®. Biotage SP1 systems®with 12g Snap-Ultra C18
columns.
HPLC system: Thermo scientific Accela with Accela pump, sample manager and autosampler
with Ascentis ®Express C18 2,7 µm, 2,1 mm x 5 cm column.
Prep-HPLC system: Waters 2545 HPLC pump. Waters 2998 PDA detector, 200-500nm. Waters
2767 sample manager. XBridge®prep C18 5µm OBDtm 19x250mm column.
HRMS: Thermo scientific LTQ Orbitrap XL + Electrospray ion source (ION-MAX).
NMR: 400 MHz Bruker Avance III HD equipped with a 5 mm SmartProbe BB/1H (BB=19F,
31P-15N).
UPLC system: Acquity UPLC H class. Acquity column manager. Acquity PDA detector.
Acquity UPLC ®BEH C18 1,7µ m. 2,1 mm x 5 cm column.
Flash chromatography: Davisil 20 - 45 µm silica.
Determination of purity by UPLC:
Column at 50°C, the same method used for all analysis. Method: 0,6ml/min. Initial 95% H2O
0,1% TFA(Trifluoroacetic acid), 5% ACN(Acetonitrile) 0,1% TFA then a linear change during
10 minutes to 5% H2O 0,1% TFA, 95% Acetonitrile 0,1% TFA.
Method for Bitoage purification
Method A: Initial 95% H2O and 5% ACN then a linear change during 20 minutes to 5% H2O
and 95% ACN
Method for prep-HPLC purification
Method A: 25 ml/min. Initial 95% H2O 0,1% TFA, 5% ACN 0,1% TFA then linear change
during 15 minutes to 5% H2O 0,1% TFA, 95% ACN 0,1% TFA.




21,9 mmol NaN3 was added to a solution containing 18 mmol 2,6-difluoronitrobenzene and
12 ml DMSO. The solution was stirred for 22 hours. The reaction was monitored using TLC.
After 22 hours the reaction mixture was extracted with 250 ml EtOAc and washed with 3 ×
250 ml distilled water. The organic phase was dried using Na2SO4 and the solvents removed by
rotavapor. The product is a yellow powder. (3,2 g, 17,6 mmol, yield = 98%)
1H-NMR: (400 MHz CDCl3) δ 7,53-7,47 (m, 1H), 7,11-7,08 (m, 1H), 7,05-7,01 (m, 1H)
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18,7 mmol 1-azide-3-fluoro-2-nitrobenzene was dissolved in 25 ml DMSO and 3,6 ml DIPEA
was added to the solution. The solution was heated to 60°C and 3,7g 1-boc-piperazine was
added to the solution and stirred for 22 hours. The reaction was monitored using TLC. The
reaction was extracted using EtOAc and washed with distilled water two times. The water
phase was washed with EtOAc. The organic phase was dried using Na2SO4 and the solvents
removed using rotavapor. The product was dissolved in DCM and dry mounted on silica and
purified on flashchromatography column. Mobile phase 15:85 EtOAc : pentane The fractions
were collected and the solvents removed using rotavapor to obtain a yellow powder. (3238mg,
yield = 50%)
1H-NMR: (400 MHz CDCl3) δ 7,43 (t, 1H), 7,0 (d, 1H), 6,95 (d, 1H), 3,5 (m, 4H), 2,92
(m, 4H), 1,46 (s, 9H)






2,92 mmol dissolved in 10 ml MeOH and added to bomb containing Pd/C and 10 ml MeOH.
Total MeOH amount: 20 ml. Hydrogenation was performed at 150 psi for 3 hours. The reaction
mixture was filtered through celite and the solvents removed using rotavapor to provide a brown
powder. (865,9 mg, yield = 101%)
1H-NMR: (400 MHz CDCl3) δ 6,67 (t, 1H), 6,58 (dd, 1H), 6,54 (dd, 1H), 3,9-3,2 (broad,
8H), 2,83 (s, 4H), 1,47 (s, 9H)
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Two parallels were done simultaneously. 1,0 mmol tert-butyl 4-(2,3-diaminophenyl)piperazine-1-
carboxylate was added to a solution containing 10 ml abs EtOH and 1 mmol tert-butylbenzaldehyde.
The reaction was stirred and refluxed at 80°C for 24 hours. The reaction was monitored using
TLC. The solvents were removed using rotavapor. The product was dry mounted on celite
and chromatographed using flashchromatography. Mobile phase 40:60 EtOAc : pentane. The
fractions were collected and the solvents evaporated using rotavapor to provide a white powder
(699,7 mg, yield 81%)
HRMS-ESI+: m/z found: 435,2754 calculated: 435,2755 1H-NMR: (400 MHz CDCl3) δ
7,98 (d, 2H), 7,49 (m, 2H), 7,16 (bs, 2H), 6,68 (bs, 1H), 3,71 (m, 4H), 3,6-3,4 (bs, 4H), 1,5 (s,









1,81 mmol tert-butyl 4-(2-(4-(tert-butyl)phenyl) -1H-benzo[d]imidazol-4-yl) piperazine-1-carboxylate
was dissolved in 30 ml 4 M HCl/Dioxane and stirred for 2 hours. The reaction mixture was ex-
tracted using distilled water and washed with 150 ml EtOAc three times. The waterphase was
lyophilised to provide an orange powder (602,9 mg, yield = 90%)
HRMS-ESI+: m/z found: 335,2231 calculated: 335,2230 1H-NMR: (400 MHz CD3OD)












0,27 mmol 2-(4-(tert-butyl)phenyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole was dissolved in
10 ml DMF. 0,16 mmol DIPEA was added to the solution and the RBF put in an icebath (0°C).
0,07 ml chloroacetyl chloride was added to the solution and stirred for 1 hour. The reaction was
monitored using TLC. The reaction mixture was extracted using distilled water and washed two
times with 25 ml DCM. The organic phase was dried using NA2SO4 and the solvents evaporated
using rotavapor. The product was dissolved in DCM and applied to Biotage precolumn and
chromatographed using Method A. The fraction were collected and lyophilised to obtain a white
powder (43,7 mg, yield = 39%)
HRMS-ESI+: m/z found:411,1958 calculated: 411,1973 1H-NMR: (400 MHz CD3OD) δ
8,05 (d, 2H), 7,59 (d, 2H), 7,20 (m, 2H), 6,76 (d, 1H), 4,34 (s, 2H), 3,92-3,86 (m, 4H), 3,44 (m,









0,198 mmmol 2-(4-(tert-butyl)phenyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole was dissolved
in 2,5 ml DMF. 0,11 ml DIPEA was added to the solution and the RBF put in to an icebath (0
°C). 0,06 ml 3-chloropropinoyl chloride was added to the solution and the solution was stirred
for 3 hours. The reaction mixture was extracted using 25 ml distilled water and washed with 30
ml DCM three times. The organic phase was washed using 20 ml brine. The solvents were re-
moved using rotavapor. The product was dissolved in DCM and added to a Biotage precolumn
and chromatographed using Method A. The fractions were collected and lyophilised to provide
a white powder. (30,9 mg, yield = 37%)
HRMS-ESI+: m/z found: 425,2100 calculated: 425,2103 1H-NMR: (400 MHz CDCl3) δ
8,0 (d, 2H), 7,56 (d, 2H), 7,30 (bs, 2H), 6,65 (bs, 1H), 3,93 (m, 2H), 3,78 (m, 2H), 3,60-3-52










0,19 mmol 2-(4-(tert-butyl)phenyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole was dissolved in
3 ml DMF. 0,11 ml DIPEA was added to the solution and the RBF put in to an icebath (0
°C). 3 eq chlorovaleroyl chloride added to the solution and stirred for 23 hours. The reaction
was monitored using TLC. The reaction mixture was extracted using 50 ml distilled water and
washed three times with 50 ml DCM. The organic phase was dried using Na2SO4 and the
solvents evaporated using rotavapor.
The product was dissolved in DCM and applied to Biotage precolumn and chromatographed
using Method A. The fractions were collected and lyophilised to obtain a white powder. (24,3
mg, yield = 28%)










0,274 mmol 2-(4-(tert-butyl)phenyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole was dissolved
in 5 ml DMF. 0,16 ml DIPEA was added to the solution and the RBF put in to an icebath (0
°C). 0,11 ml 6-chlorohexanoyl chloride was added to the solutino and the reaction mixture stirred
for 24 hours. The reaction was monitored using TLC. The reaction mixture was extracted using
50 ml distilled water and washed three times with 25 ml DCM. The organic phase was dried
using Na2SO4 and the solvents were evaporated using rotavapor.
The product was dissolved in DCM and applied to Biotage precolumn and chromatographed
using Method A. The fractions were collected and lyophilised to obtain a white powder (83,7
mg, yield = 65%)
HRMS-ESI+: m/z found: 467,2472 calculated: 467,2572 1H-NMR: (400 MHz CD3OD)
δ 8,04 (d, 2H), 7,58 (d, 2H), 7,20-7,14 (m, 2H), 6,73 (bs, 1H), 3,87 (bd, 4H), 3,59 (m, 2H), 3,31












1-one was dissolved in 2 ml ACN in a microwave vial. 0,1 ml 1M TBAF in THF added to the
solution. The reaction was performed in a microwave at 160 °C for 10 minutes. The reaction
mixture was extracted using distilled water and washed with DCM two times. The organic
phase was dried using Na2SO4 and the solvents removed using rotavapor. The product was
dissolved in DCM and applied to Biotage precolumn on chromatographed using method A The
fractions were collected and lyophilised to obtain a white powder. (6,0 mg, 30 %)
Purity: 95% HRMS-ESI+: m/z found: 395,2242 calculated: 395,2242 1H-NMR: (400
MHz CDCl3) δ 7,97 (d, 2H), 7,51 (d, 2H), 7,15 (m, 2H), 6,64 (bs, 1H), 5,12 (s, 1H), 5,01 (s,











1-one dissolved in 2 ml ACN in a microwave vial. 0,1 ml 1M TBAF in THF added to the solution.
The reaction was performed in a microwave at 160 °C for a total of 30 minutes. Samples were
taken at 0, 5, 10, 15, 20 and 30 minutes. The reaction mixture was extracted using distilled
water and washed with DCM two times. The organic phase was dried using Na2SO4 and the
solvents removed using rotavapor. The product was dissolved in DCM and applied to a Biotage
precolumn and chromatographed using Method A. No fraction contained the mass of desired
product.











6.12.1 Experiment No. 1
0,045 mmol 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-5-chloropentan-
1-one dissolved in 2 ml ACN in a microwave vial. 0,09 ml 1M TBAF in THF added to the
solution. The reaction was performed in a microwave at 160 °C for a total of 30 minutes. Sam-
ples were taken at 0, 5, 10, 15, 20 and 30 minutes. The reaction mixture was extracted using
distilled water and washed with DCM 2 times. The organic phase was dried using Na2SO4
and the solvents removed using rotavapor. The product was dissolved in DCM and applied to
a Biotage precolumn and chromatographed using Method A. The fractions were collected and
lyphillized to obtain a white powder. (3,0 mg, 15%)
Purity: 96% HRMS-ESI+: m/z found: 437,2714 calculated: 437,2711 1H-NMR: (400
MHz CDCl3) δ 8,15 (d, 2H), 7,36 (d, 2H), 7,28 (d, 1H), 7,17 (m, 1H), 6,73 (d, 1H), 4,11 (s, 2H),










6.13.1 Experiment No. 1
0,043 mmol 1-(4-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)-6-chlorohexan-
1-one dissolved in 2 ml tert-butanol. The reaction was performed in a microwave at 160 °C for
30 minutes. The reaction mixture was extracted using distilled water and washed with 20 ml
diethyl ether two times. The organic phase was dried using Na2SO4 and the solvents evapo-
rated using rotavapor. The product was run on prep-HPLC using Method A. The fractions
were collected and lyophilised to obtain a white powder (6 mg, yield = 31%)
31
6.13.2 Experiment No. 2
0,042 mmol Rx66 dissolved in 2 ml ACN. The reaction was performed in a microwave at 160 °C
for 30 minutes. The reaction mixture was extracted using distilled water and washed with 20 ml
diethyl ether two times. The organic phase was dried using Na2SO4 and the solvents evaporated
using rotavapor. The product was run on prep-HPLC using Method A. The fractions were
collected and lyophilised to obtain a white powder (3,5 mg, yield = 18%)
Purity: 95% HRMS-ESI+: m/z found: 451,2864 calculated: 451,2868 1H-NMR: (400
MHz CDCl3) δ 8,07 (d, 2H), 7,43 (d, 2H), 7,19 (m, 2H), 6,70 (d, 1H), 5,10 (s, 1H), 4,98 (s, 1H),
3,93 (bs, 2H), 3,74 (bs, 2H), 3,51 (bs, 2H), 3,42 (bs, 2H), 1,29 (s, 9H)
6.14 Serum stability
The four compounds selected for serum stability was dissolved in a solutiion of 5% ethanol, 5%
polysorbate 80 and 90% sterile water. The solutions were made to a concentration of 4 mM.
The internal standard was diluted to a concentration of 85µl
50µl compound solution was added to an eppindorf vial containing 400µl human serum
from a AB-male. The tubes were incubated at 37°C on a shaker. Aliquots of 50µl were taken
at timepoints: 0, 10, 30, 60, 120, 240 and 1320 minutes. The samples were quenched using
50µl ice cold acetonitrile. The samples were sentrifuged at 13000 rpm for 5 minutes and 50µl
of the supernatant was transferred to a HPLC-vial and diluted with the solution containing the
internal standard.
The samples were frozen until analysed on HPLC-MS. The HPLC-MS results were analysed
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